A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs
HCV PMS
Post-marketing Surveillance Study of Viekira/ Exviera Tablets for Korean Hepatitis C Patients According to the Standard for "Re-examination of New Drugs"
1 other identifier
observational
505
1 country
59
Brief Summary
Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2017
Typical duration for all trials
59 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 27, 2017
CompletedFirst Posted
Study publicly available on registry
June 28, 2017
CompletedStudy Start
First participant enrolled
August 17, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 11, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 11, 2019
CompletedOctober 8, 2020
October 1, 2020
2.2 years
June 27, 2017
October 6, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)
the lower limit of quantitation (LLOQ) SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.
12 weeks after the last dose of study drug
Secondary Outcomes (2)
Percentage of Participants With On-treatment Virologic Failure
Up to 24 weeks
Percentage of Participants With Post-treatment Relapse
From the end of treatment through 12 weeks after the last dose of study drug
Study Arms (1)
Hepatitis C
Participants with Hepatitis C receiving Viekira/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) for 12 or 24 weeks.
Eligibility Criteria
Type C Hepatitis patients who had been prescribed Viekira/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) in accordance with approved local label.
You may qualify if:
- Participants with type C hepatitis
- Participants prescribed Viekira/Exviera in accordance with approved local label
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (59)
Dong-A University Hospital /ID# 167362
Busan, Busan Gwang Yeogsi, 49201, South Korea
Pusan National University Hosp /ID# 167363
Busan, Busan Gwang Yeogsi, 602-739, South Korea
Kyungpook National Univ Hosp /ID# 168731
Daegu, Daegu Gwang Yeogsi, 41944, South Korea
Yeungnam University Med Ctr /ID# 167425
Daegu, Daegu Gwang Yeogsi, 42415, South Korea
Chungnam National University Hospital /ID# 167724
Junggu, Daejeon Gwang Yeogsi, 35015, South Korea
National health insurance cooperation ilsan hospital /ID# 201806
Goyang, Gyeonggido, 10444, South Korea
Soon Chun Hyang University Hospital Bucheon /ID# 201803
Habun, Gyeonggido, 14584, South Korea
Seoul National Univ Bundang ho /ID# 167394
Seongnam, Gyeonggido, 13620, South Korea
St. Vincent's Hospital /ID# 201660
Suwon, Gyeonggido, 16247, South Korea
Ajou University Hospital /ID# 167729
Suwon, Gyeonggido, 16499, South Korea
Inje University Busan Paik Hospital /ID# 167392
Pusan, Gyeongsangbuk-do, 47392, South Korea
Changwon Fatima Hospital /ID# 201664
Changwon, Gyeongsangnam-do, 51394, South Korea
Inha University Hospital /ID# 201802
Junggu, Incheon Gwang Yeogsi, 22332, South Korea
Chonnam National University Hospital /ID# 167423
Gwangju, Jeonranamdo, 61469, South Korea
Kwangju Christian Hospital /ID# 210823
Gwangju, Jeonranamdo, 61661, South Korea
Kyungpook National University Chilgok Hospital /ID# 201804
Daegu, Seoul Teugbyeolsi, 41404, South Korea
SMG-SNU Boramae Medical Center /ID# 201805
Dongjak-gu, Seoul Teugbyeolsi, 07061, South Korea
Kangbuk Samsung Hospital /ID# 168792
Jongno-Gu, Seoul Teugbyeolsi, 03181, South Korea
Severance Hospital /ID# 167361
Seoul, Seoul Teugbyeolsi, 03722, South Korea
Konkuk University Medical Ctr /ID# 167723
Seoul, Seoul Teugbyeolsi, 05030, South Korea
Samsung Medical Center /ID# 167722
Seoul, Seoul Teugbyeolsi, 06351, South Korea
Korea Universtiy Guro Hospital /ID# 167388
Seoul, Seoul Teugbyeolsi, 08308, South Korea
Bucheon St. Mary's hospital /ID# 170782
Bucheon-si, 420-818, South Korea
Dongnam Institute of Radiologi /ID# 167721
Busan, 46033, South Korea
Good Samsun Hospital /ID# 167365
Busan, 47007, South Korea
Haeundae Paik Hospital /ID# 170767
Busan, 48108, South Korea
Maryknoll Medical Center /ID# 167418
Busan, 48972, South Korea
Kosin University Gospel Hosp /ID# 168797
Busan, 602-702, South Korea
Samsung Changwon Hospital /ID# 167732
Changwon, 630-723, South Korea
Dankook University Hospital /ID# 167730
Cheonan, 330-715, South Korea
Chuncheon Sacred Heart Hosp /ID# 167419
Chuncheon, 200-704, South Korea
Kim Jun Hwan Sok Internal Medi /ID# 168794
Daegu, 42488, South Korea
Keimyung Univ Dongsan medical /ID# 168793
Daegu, 700-712, South Korea
Daegu Catholic University Med /ID# 167714
Daegu, 705-718, South Korea
Daegu Catholic University Med /ID# 168729
Daegu, 705-718, South Korea
The Catholic Univ. of Korea /ID# 167733
Daejeon, 301-723, South Korea
Dongguk University Ilsan Hosp /ID# 168795
Goyang, 410-773, South Korea
Myongji Hospital /ID# 170784
Goyang, 412-270, South Korea
CHA Gumi Medical Center /ID# 170783
Gumi, 39295, South Korea
Korea University Ansan Hosp /ID# 201661
Gyeonggi-do, 152-703, South Korea
Dongtan Sacred Heart Hospital /ID# 170759
Hwaseong, 18450, South Korea
The Catholic University of Korea Incheon St.Mary's Hospital /ID# 170769
Incheon, 21431, South Korea
Presbyterian Medical Center /ID# 167424
Jeonju, 54987, South Korea
CHA Bundang Medical Center /ID# 170757
Seongnam, 463-712, South Korea
Bundang Jesaeng hospital /ID# 167725
Seongnam, 463-824, South Korea
Korea University Anam Hospital /ID# 167731
Seoul, 02841, South Korea
Seoul National University Hospital /ID# 167364
Seoul, 03080, South Korea
Seoul National University Hospital /ID# 167389
Seoul, 03080, South Korea
SoonChunHyang University Seoul /ID# 167711
Seoul, 04401, South Korea
Asan Medical Center /ID# 167390
Seoul, 05505, South Korea
Chung-Ang University Hostipal /ID# 167420
Seoul, 06973, South Korea
Inje University Seoul Paik Hos /ID# 167426
Seoul, 100-032, South Korea
Inje University Sanggye Paik H /ID# 167427
Seoul, 139-707, South Korea
St. Carollo General Hospital /ID# 167712
Suncheon, 57931, South Korea
Uijeongbu St. Mary's Hospital /ID# 168730
Uijeongbu-si, 480-717, South Korea
Ulsan University Hospital /ID# 168796
Ulsan, 682-714, South Korea
Wonju Severance Christian Hosp /ID# 167713
Wŏnju, 220-701, South Korea
Pusan National University Yang /ID# 167710
Yangsan, 50612, South Korea
Yeosoo Hankook Hospital /ID# 168728
Yeosu, 59684, South Korea
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
AbbVie Inc.
AbbVie
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 27, 2017
First Posted
June 28, 2017
Study Start
August 17, 2017
Primary Completion
October 11, 2019
Study Completion
October 11, 2019
Last Updated
October 8, 2020
Record last verified: 2020-10